Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) is a pro-apoptotic member of the Bcl-2 family induced under hypoxia [3, 5, 6] . Low or absent expression has been described in several human tumors, resulting in poor prognosis [1] . We previously reported that BNIP3 expression is lost in a significant portion of invasive breast cancers, which was correlated with poor prognostic features such as positive lymph node status and high proliferation [9] . Since DNA promoter hypermethylation ("methylation") is a common mechanism to silence gene expression, contributing to tumor-progression and invasion, we further studied the relation between BNIP3 methylation and gene expression by RNA in situ hybridization (ISH) in invasive breast cancer.
In 40 cases of invasive breast cancer, BNIP3 methylation was studied by Methylation Specific Multiplex Ligation-dependent Probe Amplification [2, 4, 8, 11 ] with 2 BNIP3 probes (157 and 291) located in the CpG island harboring the BNIP3 promoter. The 157 probe is located 50 nucleotides before exon 1, while probe 291 is located in exon 1. Both probes target sequences located in the BNIP3 promoter that is located within a 1700-bp CpG island, which spans from −1162 to +538 bp of the transcription start site and contains the first exon of the BNIP3 gene. This promoter area has been reported to be methylated in pancreatic cancer [12] and in gastric and colorectal cancer [10] . Data on BNIP3 mRNA in situ hybridization were derived from a previous study [9] .
BNIP3 methylation levels in 8 normal tissue samples was on average 0.08. BNIP3 methylation was overall low (between 0.3 and 15% for probe 157 and between 0 and 31% for probe 291), while other genes included in this assay (CCND2, RASSF1, GSTP1, HIN1) showed methylation percentages up to 100% (means 24-51%) in the same tumors. Cases that were negative (N = 4) in BNIP3 RNA ISH showed higher BNIP3 methylation (p = 0.047) for probe 157 than those positive by RNA ISH (N = 36) (see Fig. 1 ), but in none of the ISH negative tumors the methylation levels exceeded 10%. This correlation therefore needs to be interpreted with care. BNIP3 methylation levels as detected by probe 291 were not significantly different (p = 0.83) between tumors with and without BNIP3 expression.
In conclusion, BNIP3 shows low levels of promoter hypermethylation in invasive breast cancer, mostly lower than the proposed 15% threshold that supposedly discriminates "true" from background methylation [7] . Although BNIP3 methylation detected with probe 157 is associated with lower BNIP3 expression at the RNA level, its low level suggests that methylation does not seem to be a major explanation for the differential BNIP3 expression in invasive breast cancer previously described [9] .
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